Invivyd shares are trading higher after the company announced PEMGARDA is available for purchase in the U.S. and said it sees initial FY24 PEMGARDA net product revenue guidance in the range of $150 million to $200 million.
$IVVD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Invivyd shares are trading higher after the company announced PEMGARDA is available for purchase in the U.S. and said it sees initial FY24 PEMGARDA net product revenue guidance in the range of $150 million to $200 million.